Medarex, Inc. and licensing partner, J&J subsidiary Centocor R&D, Inc., have extended their antibody development relationship, providing Centocor with continued access to Medarex’s UltiMAb Human Antibody Development System for the generation of fully human antibodies to an unlimited number of targets. Under the terms of the new agreement, Centocor will license Medarex’s UltiMAb technology to discover and potentially develop and commercialize antibody therapeutics. Medare...